Irinotecan (CPT-11) in combination with raltitrexed (TX) in patients with previously untreated, advanced colorectal cancer (ACC) patients.: Preliminary results of a phase I/II trial.

被引：0
|
作者：
Losa, F
Manzano, H
Vicente, P
Rifa, J
Ocaña, J
Balcells, M
Mediavilla, D
Heras, L
机构：
[1] Hosp creu Roja, Lhospitalet De Llobregat, Spain
[2] Hosp Son Dureta, Palma de Mallorca, Spain
[3] Hosp Gen Granollers, Granollers, Spain
[4] Almirall Prodesfarma SA, Barcelona, Spain
[5] Rec Clin SL, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3675
引用
收藏
页码：288S / 288S
页数：1
相关论文
共 50 条
  • [21] Phase II trial and pharmacokinetic study of irinotecan (CPT-11) in patients with glioblastoma
    Boige, V
    Raymond, E
    Fabbro, M
    Plazza, J
    Vassal, G
    Risse, ML
    Rodier, JM
    Armand, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 137 - 137
  • [22] Second line chemotherapy with irinotecan (CPT-11) and mitomycin-C (MMC) in patients with advanced/metastatic colorectal (CC) and gastric cancer (GC): A phase II trial.
    Papamichael, D
    Bamias, A
    Ioannides, G
    Syrigos, K
    Demosthenous, C
    Pavlidis, N
    ANNALS OF ONCOLOGY, 2000, 11 : 57 - 57
  • [23] Irinotecan (CPT-11) as first line treatment of patients with not pretreated advanced colorectal cancer
    Firyida, JL
    Menendez, MD
    Mel, JR
    Diz, P
    Constenla-Figueiras, M
    Casal, J
    Valladares, M
    Castellanos, J
    Balcells, M
    ANNALS OF ONCOLOGY, 1998, 9 : 38 - 39
  • [24] A phase I trial of CPT-11 and S-1 combination chemotherapy in patients with metastatic colorectal cancer
    Yamaguchi, Yoshiyuki
    Minami, Kazuhito
    Kawabuchi, Yoshiharu
    Ohshita, Akiko
    Hironaka, Katsuji
    HEPATO-GASTROENTEROLOGY, 2008, 55 (82-83) : 407 - 411
  • [25] The efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer (ACC) patients: An interim analysis of a multicenter, phase II trial.
    Liu, Yunpeng
    Teng, Zan
    Qu, Xiujuan
    Zhang, Yan Qiao
    Zheng, Zhendong
    Wen, Fugang
    Bai, Yuxian
    Piao, Ying
    Wang, Ying
    Teng, Yuee
    Zhao, Mingfang
    Jin, Bo
    Li, Xin
    Shi, Jing
    Yu, Ping
    Qu, Jinglei
    Luo, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Biweekly administration in two diferent dose levels of irinotecan (CPT-11), in patients with advanced colorectal cancer (CRC), according to toxicity prognostic factors.: A phase II trial.
    Saigí, E
    Salut, A
    Campos, JM
    Manzano, H
    Batiste-Alentom, E
    Arcusa, A
    Losa, F
    Vélez, E
    Guasch, I
    Gallego, O
    ANNALS OF ONCOLOGY, 2000, 11 : 44 - 44
  • [27] A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
    N E Schoemaker
    I E L M Kuppens
    V Moiseyenko
    B Glimelius
    M Kjaer
    H Starkhammer
    D J Richel
    R Smaaland
    K Bertelsen
    J P Poulsen
    E Voznyi
    J Norum
    D Fennelly
    K M Tveit
    A Garin
    G Gruia
    A Mourier
    D Sibaud
    P Lefebvre
    J H Beijnen
    J H M Schellens
    W W ten Bokkel Huinink
    British Journal of Cancer, 2004, 91 : 1434 - 1441
  • [28] Final result of phase II study of irinotecan (CPT-11) plus oral S-1 for previously treated advanced NSCLC patients.
    Arai, Daisuke
    Soejima, Kenzo
    Naoki, Katsuhiko
    Ikemura, Shinnosuke
    Terai, Hideki
    Sato, Takashi
    Satomi, Ryousuke
    Nakayama, Souhei
    Yoda, Satoshi
    Ishioka, Kouta
    Ohgino, Keiko
    Miyata, Jun
    Kabata, Hiroki
    Miyazaki, Masaki
    Betsuyaku, Tomoko
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Irinotecan (CPT-11) plus mitomycin C (MMC) for the second line treatment of patients (PTS) with advanced colorectal carcinoma (ACC). A phase I/II study.
    Casaretti, R
    Biglietto, M
    De Lucia, L
    De Cataldis, G
    Di Lullo, L
    Maiorino, L
    Avallone, A
    Guarrasi, R
    Comella, P
    Comella, G
    ANNALS OF ONCOLOGY, 2000, 11 : 65 - 65
  • [30] A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
    Schoemaker, NE
    Kuppens, IELM
    Moiseyenko, V
    Glimelius, B
    Kjaer, M
    Starkhammer, H
    Richel, DJ
    Smaaland, R
    Bertelsen, K
    Poulsen, JP
    Voznyi, E
    Norum, J
    Fennelly, D
    Tveit, KM
    Garin, A
    Gruia, G
    Mourier, A
    Sibaud, D
    Lefebvre, P
    Beijnen, JH
    Schellens, JHM
    Huinink, WWT
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1434 - 1441
12345